You are here: Industry Insights > treat

News List

When It Comes to Treating Infertility, Race, Education and Income Matter drugs
July 01, 2019
When It Comes to Treating Infertility, Race, Education and Income Matter.
Terns to commercialise GENFIT’s elafibranor to treat NASH and PBC pharmaceutical-technology
June 27, 2019
Terns Pharmaceuticals has signed an agreement to acquire the exclusive rights to develop, register and market GENFIT’s elafibranor.
Type 2 diabetes treatment approved for children and adolescents europeanpharmaceuticalreview
June 20, 2019
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
Genentech receives FDA approval for Polivy to treat DLBCL pharmaceutical-technology
June 13, 2019
Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab (BR) to treat diffuse large B-cell lymphoma (DLBCL) in adults.
Chemoimmunotherapy Regimen Approved to Treat DLBCL drugs
June 11, 2019
Chemoimmunotherapy Regimen Approved to Treat DLBCL.
Zonisamide may help those with dementia with Lewy bodies europeanpharmaceuticalreview
April 29, 2019
A drug used to treat seizures may effectively treat the movement symptoms in people with dementia with Lewy bodies without causing additional psychiatric symptoms…
Using the Innate Immune System to Treat Disease fiercebiotech
April 28, 2019
For most people, two of the most frightening diseases are cancer and Alzheimer’s disease. The reason is simple – these diseases are incurable.
Psychostimulant Use Pervasive in Young Adults' Fatal Strokes drugs
April 28, 2019
Psychostimulant Use Pervasive in Young Adults' Fatal Strokes.
Treatments for Tomorrow and a Vision for the Future: A Look at Innovation fiercepharma
November 27, 2018
By Marie Schiller, Vice President, Connected Care and Insulins Product Development, Eli Lilly and Company and Ruth Gimeno, Vice President, Diabetes and Metabolic Research, Diabetes and Complications Research, Eli Lilly and Company
Roivant and iNtRON sign licensing deal for SAL200 pharmaceutical
November 21, 2018
Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to treat infectious diseases caused by antibiotic-resistant staphylococci.